EHS
EHS

Rucaparib induces response in BRCA-mutated pancreatic cancer

Susan M. Domchek
Some patients with advanced pancreatic cancer who harbor BRCA1 or BRCA2 mutations derived clinical benefit from rucaparib, according to study results.
Rucaparib (Rubraca, Clovis Oncology) — a PARP inhibitor approved by FDA for maintenance treatment of certain women with ovarian, fallopian tube or primary peritoneal cancers — also exhibited a tolerable safety profile.
Susan M. Domchek, MD, executive director of Basser Center for BRCA at University of Pennsylvania’s Abramson Cancer Center, and colleagues studied 19 patients with measurable locally advanced or
EHS
Back to top button